Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company has a market capitalization of $65 billion and develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases, as well as cancer and more.
Companies with a market cap of $10 billion or more are typically referred to as “big-cap stocks.” REGN fits squarely into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the biotechnology industry.
Barclays Says Sandisk’s New AI Contracts Could Change the Memory Industry
Meta Has a Plan to Monetize Its AI Investments. Its Underperforming Stock Needs It Badly.
Why Warren Buffett Hasn’t Sold Coca-Cola Stock for Over 30 Years
Companies with a market cap of $10 billion or more are typically referred to as “big-cap stocks.” REGN fits squarely into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the biotechnology industry.
Barclays Says Sandisk’s New AI Contracts Could Change the Memory Industry
Meta Has a Plan to Monetize Its AI Investments. Its Underperforming Stock Needs It Badly.
Why Warren Buffett Hasn’t Sold Coca-Cola Stock for Over 30 Years
2 days ago
